Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02973997 · ClinicalTrials.gov registry record · Phase 2
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
A Phase 2 study, sponsored by Academic and Community Cancer Research United.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT02973997 is a Phase 2 study that has completed, run by Academic and Community Cancer Research United. The registered enrollment target is 57 participants.
The verdict
NCT02973997, a Phase 2 study, has completed, sponsored by Academic and Community Cancer Research United.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
This phase II trial studies how well pembrolizumab and lenvatinib work in treating patients with differentiated thyroid cancer that has spread to other places in the body or has come back and cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Interventions
- BIOLOGICAL Pembrolizumab
- OTHER Laboratory Biomarker Analysis
- DRUG Lenvatinib
- DRUG Lenvatinib Mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2018-02-07 |
| Est. Completion | 2023-10-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02973997
The ClinicalTrials.gov registry entry for NCT02973997 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Academic and Community Cancer Research United, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT02973997 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02973997 about?
NCT02973997 is a clinical study titled "Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)". This phase II trial studies how well pembrolizumab and lenvatinib work in treating patients with differentiated thyroid cancer that has spread to other places in the body or has come back and cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the ...
What is the current status of trial NCT02973997?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2018-02-07. Estimated completion is 2023-10-08.
What interventions are being tested in trial NCT02973997?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER), Lenvatinib (DRUG), Lenvatinib Mesylate (DRUG).
Who is sponsoring clinical trial NCT02973997?
This trial is sponsored by Academic and Community Cancer Research United, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.